Skip to main content

Table 1 Characteristics of CHD patients

From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Items Total patients (N = 214) 2-year non-ISR patients (n = 176) 2-year ISR patients (n = 38) P value
Age (years), mean ± SD 64.6 ± 9.1 64.2 ± 8.9 66.3 ± 10.0 0.199
Gender, No. (%)     0.155
 Female 40 (18.7) 36 (20.5) 4 (10.5)  
 Male 174 (81.3) 140 (79.5) 34 (89.5)  
BMI (kg/m2), mean ± SD 24.5 ± 3.6 24.5 ± 3.7 24.9 ± 3.1 0.462
Current smoke, No. (%) 55 (25.7) 43 (24.4) 12 (31.6) 0.361
Hypertension, No. (%) 150 (70.1) 119 (67.6) 31 (81.6) 0.088
Diabetes mellitus, No. (%) 63 (29.4) 43 (24.4) 20 (52.6) 0.001
Hypercholesteremia, No. (%) 135 (63.1) 104 (59.1) 31 (81.6) 0.009
Hyperuricemia, No. (%) 73 (34.1) 53 (30.1) 20 (52.6) 0.008
Family history of CAD, No. (%) 46 (21.5) 34 (19.3) 12 (31.6) 0.095
MAP (mmHg), median (IQR) 106.0 (97.0–115.0) 105.0 (96.3–116.8) 107.0 (102.0–111.3) 0.350
FBG (mmol/L), mean ± SD 5.8 ± 1.2 5.7 ± 1.3 6.2 ± 0.9 0.019
IRI, mean ± SD 2.25 ± 1.6 2.1 ± 1.5 3.0 ± 1.5 0.001
Scr (μmol/L), mean ± SD 82.7 ± 15.6 81.5 ± 14.8 88.1 ± 18.2 0.017
SUA (μmol/L), median (IQR) 333.6 (285.9–408.2) 333.3 (289.1–400.0) 365.3 (279.1–447.5) 0.309
TG (mmol/L), median (IQR) 1.8 (1.0–2.4) 1.8 (1.0–2.4) 1.9 (1.0–2.8) 0.587
TC (mmol/L), median (IQR) 4.6 (3.9–5.2) 4.5 (3.8–5.0) 4.6 (4.3–5.6) 0.069
LDL-C (mmol/L), mean ± SD 2.8 ± 0.6 2.7 ± 0.6 3.1 ± 0.6 0.002
HDL-C (mmol/L), mean ± SD 1.0 ± 0.2 1.0 ± 0.3 0.9 ± 0.2 0.024
HsCRP (mg/L), median (IQR) 4.7 (1.8–8.0) 3.9 (1.0–7.1) 7.4 (5.8–10.8)  < 0.001
ESR (mm/L), median (IQR) 12.7 (6.7–20.8) 12.3 (5.8–20.7) 13.8 (8.3–26.1) 0.137
WBC (*109/L), median (IQR) 6.1 (4.9–7.1) 6.1 (4.8–7.1) 6.3 (5.1–7.3) 0.367
Neutrophil (*109/L), mean ± SD 3.4 ± 1.0 3.4 ± 1.0 3.6 ± 1.1 0.304
LVEF (%), median (IQR) 64.0 (59.8–70.0) 64.0 (60.0–70.0) 64.0 (57.8–70.0) 0.539
cTnI (pg/mL), median (IQR) 29.5 (17.8–47.7) 29.4 (15.3–46.9) 35.5 (23.5–57.2) 0.053
NT-proBNP (pg/mL), median (IQR) 76.5 (46.8–126.1) 75.6 (44.8–122.8) 78.1 (67.0–171.6) 0.039
Multivessel artery lesions, No. (%) 164 (76.6) 127 (72.2) 37 (97.4) 0.001
Patients with two target lesions, No. (%) 77 (36.0) 56 (31.8) 21 (55.3) 0.006
Target lesion at LAD, No. (%) 128 (59.8) 104 (59.1) 24 (63.2) 0.643
Target lesion at LCX, No. (%) 82 (38.3) 61 (34.7) 21 (55.3) 0.018
Target lesion at RCA, No. (%) 81 (37.9) 67 (38.1) 14 (36.8) 0.888
Stenosis degree of target lesion (%), median (IQR) 86.0 (82.0–89.0) 86.0 (82.0–89.0) 86.0 (83.0–91.0) 0.111
Length of target lesion (mm), median (IQR) 33.5 (26.0–40.0) 33.0 (26.0–39.0) 37.0 (29.0–46.3) 0.018
Length of stent (mm), median (IQR) 37.0 (30.0–43.3) 37.0 (28.3–43.0) 40.5 (33.0–49.0) 0.016
Diameter of stent (mm), median (IQR) 3.2 (2.9–3.4) 3.3 (2.9–3.4) 3.1 (3.0–3.3) 0.209
Time of stent dilation (s), median (IQR) 16.0 (13.0–18.0) 15.0 (14.0–18.0) 16.5 (12.0–20.0) 0.731
Pre-stent balloon dilation, No. (%) 66 (30.8) 56 (31.8) 10 (26.3) 0.505
Aspirin, No. (%) 214 (100.0) 176 (100.0) 38 (100.0)
Nitrates, No. (%) 214 (100.0) 176 (100.0) 38 (100.0)
Statins, No. (%) 214 (100.0) 176 (100.0) 38 (100.0)
β-receptor blockers, No. (%) 182 (85.0) 152 (86.4) 30 (78.9) 0.245
ACEIs/ARBs, No. (%) 134 (62.6) 116 (65.9) 18 (47.4) 0.032
Calcium channel blockers, No. (%) 68 (31.8) 58 (33.0) 10 (26.3) 0.425
  1. Boldface represented P < 0.05
  2. CHD coronary heart disease, ISR in-stent restenosis, SD standard deviation, BMI body mass index, CAD coronary artery disease, MAP mean arterial pressure, IQR interquartile range, FBG fasting blood-glucose, IRI insulin resistance index, Scr serum creatinine, SUA serum uric acid, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, HsCRP high-sensitivity C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, LVEF left ventricular ejection fraction, cTnI cardiac troponin I, NT-proBNP N-terminal-proB-type natriuretic peptide, LAD left anterior descending branch, LCX left circumflex artery, RCA right coronary artery, ACEIs angiotensin converting enzymes inhibitors, ARBs angiotensin receptor blockers